Sigyn Therapeutics (SIGY) 10-K 6 Apr 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Apr. 05, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	Sigyn Therapeutics, Inc.
Entity Central Index Key	0001642159
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Public Float			$ 414,636
Entity Common Stock, Shares Outstanding		35,248,513
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash	$ 84,402
Inventories	586,047
Total current assets	670,449
Property and equipment, net	1,728
Intangible assets, net	21,905
Total assets	694,082	0
Current liabilities:
Accounts payable	16,005	910
Accrued payroll and payroll taxes	59,707
Short-term convertible notes payable, less unamortized debt issuance costs of $97,832 and $0, respectively	518,668
Other current liabilities	523
Total current liabilities	594,903	910
Total liabilities	594,903	910
Stockholders' deficit
Common stock, $0.0001 par value, 1,000,000,000 shares authorized; 35,201,513 and 500,000 shares issued and outstanding at December 31, 2020 and 2019, respectively	3,520	50
Additional paid-in-capital	1,356,799	590
Accumulated deficit	(1,261,140)	(1,550)
Total stockholders' deficit	99,179	(910)
Total liabilities and stockholders' deficit	$ 694,082	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Unamortized debt issuance costs	$ 97,832	$ 0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	35,201,513	500,000
Common stock, shares outstanding	35,201,513	500,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income - USD ($)	2 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020
Income Statement [Abstract]
Net revenues
Gross Profit
Operating expenses:
Marketing expenses		705
Research and development		27,456
General and administrative	1,550	888,273
Total operating expenses	1,550	916,434
Loss from operations	(1,550)	(916,434)
Other expense:
Interest expense		343,156
Total other expense		343,156
Loss before income taxes	(1,550)	(1,259,590)
Income taxes
Net loss and comprehensive loss.	$ (1,550)	$ (1,259,590)
Net loss per share, basic and diluted	$ 0	$ (0.17)
Weighted average number of shares outstanding
Basic and diluted	500,000	7,351,272

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Oct. 28, 2019
Balance, shares at Oct. 28, 2019
Issuance of common stock to founders	$ 50	(50)
Issuance of common stock to founders, shares	500,000
Expenses paid on behalf of company - related party		640		640
Net loss			(1,550)	(1,550)
Balance at Dec. 31, 2019	$ 50	590	(1,550)	(910)
Balance, shares at Dec. 31, 2019	500,000
Common stock issued in conjunction with reverse merger	$ 3,368	606,813		610,181
Common stock issued in conjunction with reverse merger, shares	33,686,169
Warrants issued to third parties in conjunction with debt issuance		223,560		223,560
Beneficial conversion feature in conjunction with debt issuance		129,938		129,938
Common stock issued to third parties in conjunction with exchange of debt	$ 102	395,898		396,000
Common stock issued to third parties in conjunction with exchange of debt, shares	1,015,344
Net loss			(1,259,590)	(1,259,590)
Balance at Dec. 31, 2020	$ 3,520	$ 1,356,799	$ (1,261,140)	$ 99,179
Balance, shares at Dec. 31, 2020	35,201,513

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	2 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (1,550)	$ (1,259,590)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		346
Amortization expense		10,954
Expenses paid on behalf of company - related party	640
Accretion of debt discount		275,333
Accretion of original issuance costs		67,823
Changes in operating assets and liabilities:
Accounts payable	910	15,095
Accrued payroll and payroll taxes		59,707
Other current liabilities		523
Net cash used in operating activities		(829,809)
Cash flows from investing activities:
Website development costs		(10,799)
Net cash used in investing activities		(10,799)
Cash flows from financing activities:
Proceeds from short-term convertible notes		925,010
Net cash used in financing activities		925,010
Net increase in cash		84,402
Cash at beginning of period
Cash at end of period		84,402
Cash paid during the period for:
Interest
Income taxes
Non-cash investing and financing activities:
Beneficial conversion feature in conjunction with debt issuance		129,938
Warrants issued to third parties in conjunction with debt issuance		223,560
Original issue discount issued in conjunction with debt		85,495
Common stock issued to third parties in conjunction with exchange of debt		396,000
Issuance of common stock issued to founders	$ 50

Organization and Principal Acti

Organization and Principal Activities	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Principal Activities	NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES Corporate History and Background Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) was established on October 29, 2019 in the State of Delaware. We are a development-stage therapeutic technology company that is headquartered in San Diego, California USA. Our primary focus is directed toward a significant unmet need in global health: the treatment of acute life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome (“The Cytokine Storm” or “Cytokine Release Syndrome”) and not addressed with approved drug therapies. Cytokine Storm Syndrome is a dysregulated immune response that can be induced by a wide range of infectious and non-infectious conditions. A hallmark of the Cytokine Storm is an over-production of inflammatory cytokines, which can destroy tissue, trigger multiple-organ failure and cause death. On October 19, 2020, Reign Resources Corporation, a Delaware corporation (the “Registrant”) completed a Share Exchange Agreement (the “Agreement”) with our organization (Sigyn Therapeutics) that resulted in the registrant acquiring 100% of our issued and outstanding shares of common stock in exchange for 75% of the fully paid and nonassessable shares of the Registrant’s common stock outstanding (the “Acquisition”). In conjunction with the transaction, the Registrant changed its name to Sigyn Therapeutics, Inc. pursuant to an amendment to its articles of incorporation that was filed with the State of Delaware. Subsequently, the Registrant’s trading symbol was changed to SIGY. The Acquisition was treated by the Company as a reverse merger in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). For accounting purposes, Sigyn is considered to have acquired the Registrant as the accounting acquirer because: (i) Sigyn stockholders own 75% of the combined company, on an as-converted basis, immediately following the Closing Date, (ii) Sigyn directors hold a majority of board seats in the combined company and (iii) Sigyn management held all key positions in the management of the combined company. Accordingly, Sigyn’s historical results of operations will replace the registrant’s historical results of operations for all periods prior to the Acquisition and, for all periods following the Acquisition, the results of operations of the combined company will be included in the Company’s financial statements. The Acquisition was treated as a “tax-free exchange” under Section 368 of the Internal Revenue Code of 1986 and resulted in the Additionally, assets held on the books of Reign Resources Corporation, such as Gem inventory, was kept in the Company and therefore recorded as assets on the Share Exchange date. As of April 5, 2021, we have a total 35,248,513 shares issued and outstanding, of which 9,561,513 shares are held by non-affiliate shareholders. About Sigyn Therapy Sigyn Therapy is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Sigyn Therapy’s mechanism of action allows for it to be implemented on the established infrastructure of dialysis and CRRT machines that are already located in hospitals and clinics worldwide. Cytokine Storm Syndrome is a hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure such as Hepatic Encephalopathy, which is associated with elevated levels of toxins and inflammatory cytokines in the bloodstream. Recent Developments On December 1, 2020, we reported the results of an in vitro We are also evaluating the ability of Sigyn Therapy to address CytoVesicles that transport inflammatory cytokine cargos throughout the bloodstream. Based on recent peer-reviewed publications and emerging scientific evidence, we believe the simultaneous clearance of circulating CytoVesicles, endotoxin and inflammatory cytokines may overcome the limitations of previous drug and medical device candidates to treat sepsis and other life-threatening inflammatory conditions. On January 6, 2021, we disclosed the results of an in vitro in vitro in vitro The Company has begun its planned principal operations, and accordingly, the Company has prepared its consolidated financial statements in accordance with US GAAP.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	NOTE 2 – BASIS OF PRESENTATION The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and include all adjustments necessary for the fair presentation of the Company’s financial position and results of operations for the periods presented. The Company currently operates in one business segment. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of businesses or separate business entities. Going Concern The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of approximately $1,261,000 at December 31, 2020, had working capital of approximately $76,000 and a working capital deficit of $1,000 at December 31, 2020 and 2019, respectively, had a net loss of approximately $1,260,000 for the year ended December 31, 2020, and net cash used in operating activities of approximately $830,000 for the year ended December 31, 2020, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company’s ability to continue as a going concern. While the Company is attempting to expand operations and increase revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of a private offering or an asset sale transaction. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While management believes in the viability of its strategy to generate revenues and in its ability to raise additional funds or transact an asset sale, there can be no assurances to that effect or on terms acceptable to the Company. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to GAAP and have been consistently applied in the preparation of the financial statements. Use of Estimates The preparation of these financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the financial statements. The more significant estimates and assumptions by management include among others: common stock valuation, and the recoverability of intangibles. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions. Cash The Company’s cash is held in bank accounts in the United States and is insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. The Company has not experienced any cash losses. Income Taxes The Company is treated as a partnership for income tax purposes; accordingly, income taxes have not been provided for in the accompanying financial statements. All of the Company’s income or losses are passed through to its members. Advertising and Marketing Costs Advertising expenses are recorded as general and administrative expenses when they are incurred. There was no advertising expense for the periods presented. Inventories Inventories are stated at the lower of cost or market (net realizable value) on a lot basis each quarter. A lot is determined by the cut, clarity, size, and weight of the sapphires. Inventory consists of sapphire jewels that meet rigorous grading criteria and are of cuts and sizes most commonly used in the jewelry industry. Inventory consists loose sapphire jewels, jewelry for sale on our website, and jewelry held as samples. Samples are used to show potential customers what the jewelry would look like. Promotional items given to customers that are not expected to be returned will be removed from inventory and expensed. There have been no promotional items given to customers as of December 31, 2020. The Company performs its own in-house assessment based on gem guide and the current market price for metals to value its inventory on an annual basis or if circumstances dictate sooner to determine if the estimated fair value is greater or less than cost. In addition, the inventory is reviewed each quarter by the Company against industry prices from gem-guide and if there is a potential impairment, the Company would appraise the inventory. The estimated fair value is subject to significant change due to changes in popularity of cut, perceived grade of the clarity of the sapphires, the number, type and size of inclusions, the availability of other similar quality and size sapphires, and other factors. As a result, the internal assessed value of the sapphires could be significantly lower from the current estimated fair value. Loose sapphire jewels do not degrade in quality over time. Property and Equipment Property and equipment are carried at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally five years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. Fixed assets are examined for the possibility of decreases in value when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. Intangible Assets Intangible assets consist primarily of website development costs. Our intangible assets are being amortized on a straight-line basis over a period of three years. Assignment of Patent On January 8, 2020, James Joyce, the Company’s CEO and Craig Roberts, the Company’s COO, assigned to the Company the rights to patent 62/881,740 pertaining to the devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood. Impairment of Long-lived Assets We periodically evaluate whether the carrying value of property, equipment and intangible assets has been impaired when circumstances indicate the carrying value of those assets may not be recoverable. The carrying amount is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If the carrying value is not recoverable, the impairment loss is measured as the excess of the asset’s carrying value over its fair value. Our impairment analyses require management to apply judgment in estimating future cash flows as well as asset fair values, including forecasting useful lives of the assets, assessing the probability of different outcomes, and selecting the discount rate that reflects the risk inherent in future cash flows. If the carrying value is not recoverable, we assess the fair value of long-lived assets using commonly accepted techniques, and may use more than one method, including, but not limited to, recent third-party comparable sales and discounted cash flow models. If actual results are not consistent with our assumptions and estimates, or our assumptions and estimates change due to new information, we may be exposed to an impairment charge in the future. For the year ended December 31, 2020 and from inception (October 29, 2019) through December 31, 2019, the Company had not experienced impairment losses on its long-lived assets. Fair Value of Financial Instruments The provisions of accounting guidance, FASB Topic ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2020, the fair value of cash, accounts payable, accrued expenses, and notes payable approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates. Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows: ● Level 1 – Quoted prices in active markets for identical assets or liabilities. ● Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities The carrying value of financial assets and liabilities recorded at fair value are measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. There were no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. There have been no transfers between levels. Basic and diluted earnings per share Diluted earnings (loss) per share are computed on the basis of the weighted average number of common shares (including common stock subject to redemption) plus dilutive potential common shares outstanding for the reporting period. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. There were no potential dilutive securities outstanding for the year ended December 31, 2020 and for the period from inception (October 29, 2019) through December 31, 2019. Stock Based Compensation In accordance with ASC No. 718, Compensation – Stock Compensation Equity Based Payments to Non-Employees Concentrations, Risks, and Uncertainties Business Risk Substantial business risks and uncertainties are inherent to an entity, including the potential risk of business failure. The Company is headquartered and operates in the United States. To date, the Company has generated no revenues from operations. There can be no assurance that the Company will be able to raise additional capital and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. Also, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. Currently, these contingencies include general economic conditions, price of components, competition, and governmental and political conditions. Interest rate risk Financial assets and liabilities do not have material interest rate risk. Credit risk The Company is exposed to credit risk from its cash in banks. The credit risk on cash in banks is limited because the counterparties are recognized financial institutions. Seasonality The business is not subject to substantial seasonal fluctuations. Major Suppliers Sigyn Therapy is comprised of components that are supplied by various industry vendors. Additionally, the Company is reliant on third-party organizations to conduct clinical development studies that are necessary to advance Sigyn Therapy toward the marketplace. Should the relationship with an industry vendor or third-party clinical development organization be interrupted or discontinued, it is believed that alternate component suppliers and third-party clinical development organizations could be identified to support the continued advancement of Sigyn Therapy. Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. In August 2018, the FASB issued ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes. Income Taxes Other recently issued accounting updates are not expected to have a material impact on the Company’s consolidated financial statements.

Equipment

Equipment	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Equipment	NOTE 4 – Equipment Equipment consisted of the following as of: December 31, December 31, Estimated Life 2020 2019 Office equipment 5 years $ 2,074 $ - Accumulated depreciation (346 ) - $ 1,728 $ - Depreciation expense was $346 and $0 for the years ended December 31, 2020 and for the period from inception (October 29, 2019) through December 31, 2019, and is classified in general and administrative expenses in the consolidated Statements of Operations and Comprehensive Income.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	NOTE 5 – INTANGIBLE ASSETS Intangible assets consisted of the following as of: December 31, December 31, Estimated life 2020 2019 Trademarks 3 years $ 22,060 $ - Website 10,799 - Accumulated amortization (10,954 ) - $ 21,905 $ - As of December 31, 2020, estimated future amortization expenses related to intangible assets were as follows: Intangible Assets 2021 $ 16,207 2022 3,600 2023 2,098 $ 21,905 The Company had amortization expense of $10,954, and $0 for the year ended December 31, 2020 and for the period from inception (October 29, 2019) through December 31, 2019, respectively. On January 8, 2020, James Joyce, the Company’s CEO and Craig Roberts, the Company’s COO, assigned to the Company the rights to patent 62/881,740 pertaining to the devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood.

Convertible Promissory Debentur

Convertible Promissory Debentures	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Convertible Promissory Debentures	NOTE 6 – Convertible Promissory DEBENTURES Convertible notes payable consisted of the following: December 31, 2020 December 31, 2019 January 28, 2020 ($385,000) $ 385,000 $ - June 23, 2020 ($50,000) 50,000 - September 17, 2020 ($181,500) 181,500 - Total convertible notes payable 616,500 - Original issue discount (19,667 ) Debt discount (78,165 ) - Total convertible notes payable $ 518,668 $ - Principal payments on convertible promissory debentures are due as follows: Year ending December 31, 2021 $ 518,668 Osher – $385,000 On January 28, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.094 per share, as amended on October 20, 2020, subject to adjustment as provided therein . The Company and Osher amended the convertible debt agreement as follows on October 20, 2020: ● The parties amended the Warrants dated January 28, 2020, for the number of warrant shares from 80,209 warrant shares to 4,113,083 warrant shares at an exercise price of $0.14 per share. ● The parties amended the Note for the maturity date from June 23, 2021 to October 20, 2021. Osher – $50,000 (as amended on October 20, 2020 to $55,000) On June 23, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.39 per share, as amended on October 20, 2020, subject to adjustment as provided therein . The Company and Osher amended the convertible debt agreement as follows on October 20, 2020: ● The parties amended the Note for the aggregate principal amount from $50,000 to $55,000. The aggregate cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $50,005 which was issued at an amended $4,995 original issue discount from the face value of the Note. ● The parties amended the Warrants dated June 23, 2020, for the number of warrant shares from 10,000 warrant shares to 141,020 warrant shares at an exercise price of $0.59 per share. ● The parties amended the Note for the maturity date from June 23, 2021 to October 20, 2021. Brio – $50,000 (as amended on October 20, 2020 to $55,000) On June 23, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with respect to the sale and issuance to institutional investor Brio Capital Maser Fund, Ltd. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.39 per share, as amended on October 20, 2020, subject to adjustment as provided therein . The Company and Brio amended the convertible debt agreement as follows on October 20, 2020: ● The parties amended the Note for the aggregate principal amount from $50,000 to $55,000. The aggregate cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants was $50,000 which was issued at an amended $5,000 original issue discount from the face value of the Note. ● The parties amended the Warrants dated June 23, 2020, for the number of warrant shares from 10,000 warrant shares to 141,020 warrant shares at an exercise price of $0.59 per share. ● The parties amended the Note for the maturity date from June 23, 2021 to October 20, 2021. On December 2, 2020, Brio elected to convert the aggregate principal amount of the Note, $55,000, into 141,020 common shares. Wetzel - $25,000 (as amended on October 20, 2020 to $27,500) On August 18, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with respect to the sale and issuance to institutional investor Christopher Wetzel The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.39 per share, as amended on October 20, 2020, subject to adjustment as provided therein . The Company and Wetzel amended the convertible debt agreement as follows on October 20, 2020: ● The parties amended the Note for the aggregate principal amount from $25,000 to $27,500. The aggregate cash subscription amount received by the Company from Wetzel for the issuance of the Note and Warrants was $25,000 which was issued at an amended $2,500 original issue discount from the face value of the Note. ● The parties amended the Warrants dated August 18, 2020, for the number of warrant shares from 5,000 warrant shares to 70,510 warrant shares at an exercise price of $0.59 per share. ● The parties amended the Note for the maturity date from August 18, 2021 to October 20, 2021. On October 28, 2020, Wetzel elected to convert the aggregate principal amount of the Note, $27,500, into 70,510 common shares. Osher – $181,500 On September 17, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.39 per share, as amended on October 20, 2020, subject to adjustment as provided therein . The Company and Osher amended the convertible debt agreement as follows on October 20, 2020: ● The parties amended the Warrants dated September 17, 2020, for the number of warrant shares from 8,250 warrant shares to 465,366 warrant shares at an exercise price of $0.59 per share. ● The parties amended the Note for the maturity date from September 30, 2021 to October 20, 2021. Brio – $93,500 On September 18, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with respect to the sale and issuance to institutional investor Brio Capital Maser Fund, Ltd. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.39 per share, as amended on October 20, 2020, subject to adjustment as provided therein . The Company and Brio amended the convertible debt agreement as follows on October 20, 2020: ● The parties amended the Warrants dated September 18, 2020, for the number of warrant shares from 4,250 warrant shares to 239,734 warrant shares at an exercise price of $0.59 per share. ● The parties amended the Note for the maturity date from September 30, 2021 to October 20, 2021. On December 2, 2020, Brio elected to convert the aggregate principal amount of the Note, $93,500, into 239,734 common shares. Eisenberger - $165,000 On September 21, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with respect to the sale and issuance to institutional investor Joseph Eisenberger Eisenberger Eisenberger Eisenberger The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.39 per share, as amended on October 20, 2020, subject to adjustment as provided therein . The Company and Eisenberger amended the convertible debt agreement as follows on October 20, 2020: ● The parties amended the number of shares from the Warrants dated September 21, 2020, for the number of warrant shares from 7,500 warrant shares to 423,060 warrant shares at an exercise price of $0.59 per share. ● The parties amended the Note for the maturity date from September 30, 2021 to October 20, 2021. On November 5, 2020, Eisenberger elected to convert the aggregate principal amount of the Note, $165,000, into 423,060 common shares. DiMaggio – $27,500 (as amended on October 20, 2020 to $22,000) On September 28, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with respect to the sale and issuance to institutional investor Ross DiMaggio The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.39 per share, as amended on October 20, 2020, subject to adjustment as provided therein . The Company and DiMaggio amended the convertible debt agreement as follows on October 20, 2020: ● The parties amended the Note for the aggregate principal amount from $27,500 to $22,000. The aggregate cash subscription amount received by the Company from Wetzel for the issuance of the Note and Warrants was $20,000 which was issued at an amended $2,000 original issue discount from the face value of the Note. ● The parties amended the Warrants dated September 28, 2020, for the number of warrant shares from 1,000 warrant shares to 56,408 warrant shares at an exercise price of $0.59 per share. ● The parties amended the Note for the maturity date from August 18, 2021 to October 20, 2021. On October 27, 2020, DiMaggio elected to convert the aggregate principal amount of the Note, $22,000, into 56,408 common shares. Unger – $33,000 On September 29, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with respect to the sale and issuance to institutional investor David W. Unger The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.39 per share, as amended on October 20, 2020, subject to adjustment as provided therein . The Company and Unger amended the convertible debt agreement as follows on October 20, 2020: ● The parties amended the Warrants dated September 29, 2020, for the number of warrant shares from 1,500 warrant shares to 84,612 warrant shares at an exercise price of $0.59 per share. ● The parties amended the Note for the maturity date from August 18, 2021 to October 20, 2021. On October 26, 2020, Unger elected to convert the aggregate principal amount of the Note, $33,000, into 84,612 common shares.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Deficit	NOTE 7 – STOCKHOLDERS’ DEFICIT The Company issued 500,000 restricted common shares to founder’s, valued at $50 (based on the par value on the date of grant). The issuance was an isolated transaction not involving a public offering pursuant to Section 4(2) of the Securities Act of 1933. The Company has authorized 1,000,000,000 shares of par value $0.0001 common stock, of which 500,000 shares are outstanding at December 31, 2019. On October 19, 2020, the Company issued 33,685,876 common shares in conjunction with acquisition (see Note 1). During the year ended December 31, 2020, the Company issued 1,015,344 common shares to third parties in conjunction with the exchange of convertible promissory debentures (see Note 7).

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 8 – Related Party Transactions Other than as set forth below, and as disclosed in Notes 5 and 6, there have not been any transaction entered into or been a participant in which a related person had or will have a direct or indirect material interest. Employment Agreements Mr. Joyce receives an annual base salary of $455,000, plus bonus compensation not to exceed 50% of salary. Mr. Joyce’s employment also provides for medical insurance, disability benefits and one year of severance pay if his employment is terminated without cause or due to a change in control. Additionally, the Company has agreed to maintain a beneficial ownership target of 9% for Mr. Joyce. Mr. Joyce’s compensation was approved by the Reign Resources Corporation Board of Directors on October 6, 2020 and was among conditions of the Share Exchange Agreement that was completed with Sigyn Therapeutics on October 19, 2020. The Company incurred compensation expense of $418,842 and $0 and employee benefits of $22,516 and $0 for the year ended December 31, 2020 and from date of formation (October 29, 2019) through December 31, 2019, respectively. Sigyn had no employment agreement with its COO but Sigyn still incurred compensation on behalf of the COO. The Company incurred compensation expense of $233,981 and $0 and employee benefits of $22,024 and $0 for the year ended December 31, 2020 and from date of formation (October 29, 2019) through December 31, 2019, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 9 – INCOME TAXES At December 31, 2020, net operating loss carry forwards for Federal and state income tax purposes totaling approximately $1,229,000 available to reduce future income which under the Tax Cuts and Jobs Act of 2018, allows for an indefinite carryforward period, with carryforwards limited to 80% of each subsequent year’s net income. There is no income tax affect due to the recognition of a full valuation allowance on the expected tax benefits of future loss carry forwards based on uncertainty surrounding realization of such assets. A reconciliation of the statutory income tax rates and the effective tax rate is as follows: From Inception (October 29, 2019) through December 31, December 31, 2020 2019 Statutory U.S. federal rate 21.0 % 21.0 % State income tax, net of federal benefit 7.0 % 7.0 % Permanent differences 0.0 % 0.0 % Valuation allowance (28.0 )% (28.0 )% Provision for income taxes 0.0 % 0.0 % The tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following: December 31, 2020 2019 Deferred tax assets: Net operating loss carry forwards $ 352,912 $ 434 Valuation allowance (352,912 ) (434 ) $ - $ - Major tax jurisdictions are the United States and California. All of the tax years will remain open three and four years for examination by the Federal and state tax authorities, respectively, from the date of utilization of the net operating loss. There are no tax audits pending.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Earnings Per Share	NOTE 10 – EARNINGS PER SHARE FASB ASC Topic 260, Earnings Per Share Basic earnings (loss) per share are computed by dividing net earnings available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Basic and diluted earnings (loss) per share are the same since net losses for all periods presented and including the additional potential common shares would have an anti-dilutive effect. The following table sets forth the computation of basic and diluted net income per share: From Inception (October 29, 2019) Year Ended December 31, through December 31, 2020 2019 Net loss attributable to the common stockholders $ (1,259,590 ) $ (1,550 ) Basic weighted average outstanding shares of common stock 7,351,272 500,000 Dilutive effect of options and warrants - - Diluted weighted average common stock and common stock equivalents 7,351,272 500,000 Loss per share: Basic and diluted $ (0.17 ) $ (0.00 )

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 11 – COMMITMENTS AND CONTINGENCIES Legal From time to time, various lawsuits and legal proceedings may arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any legal proceedings or claims that it believes will have a material adverse effect on its business, financial condition or operating results.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 12 – SUBSEQUENT EVENTS The Company evaluated all events or transactions that occurred after December 31, 2020 up through the date the financial statements were available to be issued. During this period, the Company did not have any material recognizable subsequent events required to be disclosed as of and for the period ended December 31, 2020 except for the following: Convertible Promissory Debentures Osher – $110,000 On February 10, 2021, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.70 per share, subject to adjustment as provided therein . Brio – $110,000 On February 10, 2021, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.70 per share, subject to adjustment as provided therein . Common Stock On January 14, 2021, the Company issued a total of 47,000 shares of its common stock valued at $82,250 (based on the stock price of the Company’s common stock on the date of issuance) to a third party, for marketing and to promote brand awareness.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of these financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the financial statements. The more significant estimates and assumptions by management include among others: common stock valuation, and the recoverability of intangibles. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.
Cash	Cash The Company’s cash is held in bank accounts in the United States and is insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. The Company has not experienced any cash losses.
Income Taxes	Income Taxes The Company is treated as a partnership for income tax purposes; accordingly, income taxes have not been provided for in the accompanying financial statements. All of the Company’s income or losses are passed through to its members.
Advertising and Marketing Costs	Advertising and Marketing Costs Advertising expenses are recorded as general and administrative expenses when they are incurred. There was no advertising expense for the periods presented.
Inventories	Inventories Inventories are stated at the lower of cost or market (net realizable value) on a lot basis each quarter. A lot is determined by the cut, clarity, size, and weight of the sapphires. Inventory consists of sapphire jewels that meet rigorous grading criteria and are of cuts and sizes most commonly used in the jewelry industry. Inventory consists loose sapphire jewels, jewelry for sale on our website, and jewelry held as samples. Samples are used to show potential customers what the jewelry would look like. Promotional items given to customers that are not expected to be returned will be removed from inventory and expensed. There have been no promotional items given to customers as of December 31, 2020. The Company performs its own in-house assessment based on gem guide and the current market price for metals to value its inventory on an annual basis or if circumstances dictate sooner to determine if the estimated fair value is greater or less than cost. In addition, the inventory is reviewed each quarter by the Company against industry prices from gem-guide and if there is a potential impairment, the Company would appraise the inventory. The estimated fair value is subject to significant change due to changes in popularity of cut, perceived grade of the clarity of the sapphires, the number, type and size of inclusions, the availability of other similar quality and size sapphires, and other factors. As a result, the internal assessed value of the sapphires could be significantly lower from the current estimated fair value. Loose sapphire jewels do not degrade in quality over time.
Property and Equipment	Property and Equipment Property and equipment are carried at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally five years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. Fixed assets are examined for the possibility of decreases in value when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.
Intangible Assets	Intangible Assets Intangible assets consist primarily of website development costs. Our intangible assets are being amortized on a straight-line basis over a period of three years. Assignment of Patent On January 8, 2020, James Joyce, the Company’s CEO and Craig Roberts, the Company’s COO, assigned to the Company the rights to patent 62/881,740 pertaining to the devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood.
Impairment of Long-lived Assets	Impairment of Long-lived Assets We periodically evaluate whether the carrying value of property, equipment and intangible assets has been impaired when circumstances indicate the carrying value of those assets may not be recoverable. The carrying amount is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If the carrying value is not recoverable, the impairment loss is measured as the excess of the asset’s carrying value over its fair value. Our impairment analyses require management to apply judgment in estimating future cash flows as well as asset fair values, including forecasting useful lives of the assets, assessing the probability of different outcomes, and selecting the discount rate that reflects the risk inherent in future cash flows. If the carrying value is not recoverable, we assess the fair value of long-lived assets using commonly accepted techniques, and may use more than one method, including, but not limited to, recent third-party comparable sales and discounted cash flow models. If actual results are not consistent with our assumptions and estimates, or our assumptions and estimates change due to new information, we may be exposed to an impairment charge in the future. For the year ended December 31, 2020 and from inception (October 29, 2019) through December 31, 2019, the Company had not experienced impairment losses on its long-lived assets.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The provisions of accounting guidance, FASB Topic ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2020, the fair value of cash, accounts payable, accrued expenses, and notes payable approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.
Fair Value Measurements	Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows: ● Level 1 – Quoted prices in active markets for identical assets or liabilities. ● Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities The carrying value of financial assets and liabilities recorded at fair value are measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. There were no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. There have been no transfers between levels.
Basic and Diluted Earnings Per Share	Basic and diluted earnings per share Diluted earnings (loss) per share are computed on the basis of the weighted average number of common shares (including common stock subject to redemption) plus dilutive potential common shares outstanding for the reporting period. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. There were no potential dilutive securities outstanding for the year ended December 31, 2020 and for the period from inception (October 29, 2019) through December 31, 2019.
Stock Based Compensation	Stock Based Compensation In accordance with ASC No. 718, Compensation – Stock Compensation Equity Based Payments to Non-Employees
Concentrations, Risks, and Uncertainties	Concentrations, Risks, and Uncertainties Business Risk Substantial business risks and uncertainties are inherent to an entity, including the potential risk of business failure. The Company is headquartered and operates in the United States. To date, the Company has generated no revenues from operations. There can be no assurance that the Company will be able to raise additional capital and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. Also, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. Currently, these contingencies include general economic conditions, price of components, competition, and governmental and political conditions. Interest rate risk Financial assets and liabilities do not have material interest rate risk. Credit risk The Company is exposed to credit risk from its cash in banks. The credit risk on cash in banks is limited because the counterparties are recognized financial institutions. Seasonality The business is not subject to substantial seasonal fluctuations. Major Suppliers Sigyn Therapy is comprised of components that are supplied by various industry vendors. Additionally, the Company is reliant on third-party organizations to conduct clinical development studies that are necessary to advance Sigyn Therapy toward the marketplace. Should the relationship with an industry vendor or third-party clinical development organization be interrupted or discontinued, it is believed that alternate component suppliers and third-party clinical development organizations could be identified to support the continued advancement of Sigyn Therapy.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. In August 2018, the FASB issued ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes. Income Taxes Other recently issued accounting updates are not expected to have a material impact on the Company’s consolidated financial statements.

Equipment (Tables)

Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Equipment	Equipment consisted of the following as of: December 31, December 31, Estimated Life 2020 2019 Office equipment 5 years $ 2,074 $ - Accumulated depreciation (346 ) - $ 1,728 $ -

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following as of: December 31, December 31, Estimated life 2020 2019 Trademarks 3 years $ 22,060 $ - Website 10,799 - Accumulated amortization (10,954 ) - $ 21,905 $ -
Schedule of Estimated Future Amortization Expense Related to Intangible Assets	As of December 31, 2020, estimated future amortization expenses related to intangible assets were as follows: Intangible Assets 2021 $ 16,207 2022 3,600 2023 2,098 $ 21,905

Convertible Promissory Debent_2

Convertible Promissory Debentures (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable consisted of the following: December 31, 2020 December 31, 2019 January 28, 2020 ($385,000) $ 385,000 $ - June 23, 2020 ($50,000) 50,000 - September 17, 2020 ($181,500) 181,500 - Total convertible notes payable 616,500 - Original issue discount (19,667 ) Debt discount (78,165 ) - Total convertible notes payable $ 518,668 $ -
Schedule of Principal Payments Due on Convertible Promissory Debentures	Principal payments on convertible promissory debentures are due as follows: Year ending December 31, 2021 $ 518,668

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Reconciliation of Statutory Income Tax Rates and Effective Tax Rate	A reconciliation of the statutory income tax rates and the effective tax rate is as follows: From Inception (October 29, 2019) through December 31, December 31, 2020 2019 Statutory U.S. federal rate 21.0 % 21.0 % State income tax, net of federal benefit 7.0 % 7.0 % Permanent differences 0.0 % 0.0 % Valuation allowance (28.0 )% (28.0 )% Provision for income taxes 0.0 % 0.0 %
Schedule of Deferred Tax Assets	The tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following: December 31, 2020 2019 Deferred tax assets: Net operating loss carry forwards $ 352,912 $ 434 Valuation allowance (352,912 ) (434 ) $ - $ -

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Income Per Share	The following table sets forth the computation of basic and diluted net income per share: From Inception (October 29, 2019) Year Ended December 31, through December 31, 2020 2019 Net loss attributable to the common stockholders $ (1,259,590 ) $ (1,550 ) Basic weighted average outstanding shares of common stock 7,351,272 500,000 Dilutive effect of options and warrants - - Diluted weighted average common stock and common stock equivalents 7,351,272 500,000 Loss per share: Basic and diluted $ (0.17 ) $ (0.00 )

Organization and Principal Ac_2

Organization and Principal Activities (Details Narrative) - USD ($)	Oct. 19, 2020	Apr. 05, 2021	Dec. 31, 2020	Dec. 31, 2019
Common stock, issued			35,201,513	500,000
Common stock, outstanding			35,201,513	500,000
Subsequent Event [Member]
Common stock, issued		35,248,513
Common stock, outstanding		35,248,513
Non-affiliate Shareholders [Member] | Subsequent Event [Member]
Common stock, issued		9,561,513
Common stock, outstanding		9,561,513
Share Exchange Agreement [Member]
Percentage of acquisition ownership interest	100.00%
Percentage of common stock outstanding	75.00%
Converted liabilities	$ 3,429,516
Conversion shares	7,907,351
Share Exchange Agreement [Member] | Sigyn Stockholders [Member]
Percentage of acquisition ownership interest	75.00%

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	2 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020
Accounting Policies [Abstract]
Accumulated deficit	$ (1,550)	$ (1,261,140)
Working capital (deficit)	(1,000)	76,000
Net loss	(1,550)	(1,259,590)
Net cash used in operating activities		$ (829,809)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	2 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020
Accounting Policies [Abstract]
FDIC amount		$ 250,000
Advertising expenses	$ 0	$ 0
Estimated useful life for property and equipment		5 years
Intangible assets amortization period		3 years
Impairment of long-lived assets	$ 0	$ 0
Potential dilutive securities	0	0
Stock based compensation	$ 0	$ 0

Equipment (Details Narrative)

Equipment (Details Narrative) - USD ($)	2 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense		$ 346

Equipment - Schedule of Equipme

Equipment - Schedule of Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Estimated useful life	5 years
Total	$ 1,728
Office Equipment [Member]
Estimated useful life	5 years
Equipment gross	$ 2,074
Accumulated depreciation	(346)
Total	$ 1,728

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	2 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 0	$ 10,954

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Estimated life	3 years
Accumulated amortization	$ (10,954)
Total	$ 21,905
Trademarks [Member]
Estimated life	3 years
Intangible assets gross	$ 22,060
Website [Member]
Intangible assets gross	$ 10,799

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Estimated Future Amortization Expense Related to Intangible Assets (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 16,207
2022	3,600
2023	2,098
Total	$ 21,905

Convertible Promissory Debent_3

Convertible Promissory Debentures (Details Narrative) - USD ($)

Oct. 20, 2020

Sep. 29, 2020

Sep. 28, 2020

Sep. 21, 2020

Sep. 18, 2020

Sep. 17, 2020

Aug. 18, 2020

Jun. 23, 2020

Jan. 28, 2020

Jan. 28, 2020

Oct. 20, 2021

Jun. 23, 2021

Dec. 31, 2020

Dec. 02, 2020

Nov. 05, 2020

Oct. 28, 2020

Oct. 27, 2020

Oct. 26, 2020

Dec. 31, 2019

Original issue discount amount

$ 78,165

Convertible Promissory Note One [Member]

Debt instrument maturity date

Oct. 20, 2021

Convertible Promissory Note One [Member] | Securities Purchase Agreement [Member] | Osher [Member]

Aggregate principal amount of debt

$ 50,000

$ 385,000

$ 385,000

Debt instrument maturity date

Jan. 26, 2021

Jun. 23, 2021

Debt conversion, description

(i) $385,000 aggregate principal amount of Original Issue Discount Senior Convertible Debenture due January 26, 2021, based on $1.00 for each $0.90909 paid by Osher

Term of warrants

5 years

5 years

5 years

Aggregate number of warrants to purchase shares

10,000

80,209

80,209

Exercise price of warrants per share

$ 30

$ 7

$ 7

Proceeds from issuance of convertible debt

$ 350,005

$ 50,005

Original issue discount amount

$ 0

$ 34,995

$ 34,995

Debt instrument conversion price per share

$ 0.39

$ 0.094

$ 0.094

Convertible Promissory Note One [Member] | Amended Convertible Debt Agreement [Member] | Osher [Member]

Debt instrument maturity date

Oct. 20, 2021

Debt conversion, description

(i) $50,000 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the "Note") due June 23, 2021, based on $1.00 for each $0.90909 paid by Osher

Aggregate number of warrants to purchase shares

4,113,083

Exercise price of warrants per share

$ 0.14

Convertible Promissory Note One [Member] | Amended Convertible Debt Agreement Two [Member] | Osher [Member]

Aggregate principal amount of debt

$ 55,000

Debt instrument maturity date

Oct. 20, 2021

Aggregate number of warrants to purchase shares

141,020

Exercise price of warrants per share

$ 0.59

Proceeds from issuance of convertible debt

$ 4,995

Convertible Promissory Note Two [Member]

Debt instrument maturity date

Oct. 20, 2021

Convertible Promissory Note Two [Member] | Securities Purchase Agreement [Member] | Brio Capital Maser Fund, Ltd [Member]

Aggregate principal amount of debt

$ 50,000

$ 141,020

Debt instrument maturity date

Jun. 23, 2021

Debt conversion, description

(i) $50,000 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the "Note") due June 23, 2021, based on $1.00 for each $0.90909 paid by Osher

Term of warrants

5 years

Aggregate number of warrants to purchase shares

10,000

Exercise price of warrants per share

$ 30

Proceeds from issuance of convertible debt

$ 50,000

Original issue discount amount

$ 0

Debt instrument conversion price per share

$ 0.39

Convertible Promissory Note Two [Member] | Amended Convertible Debt Agreement [Member] | Brio Capital Maser Fund, Ltd [Member]

Aggregate principal amount of debt

$ 55,000

Debt instrument maturity date

Oct. 20, 2021

Aggregate number of warrants to purchase shares

141,020

Exercise price of warrants per share

$ 0.59

Proceeds from issuance of convertible debt

$ 50,000

Original issue discount amount

5,000

Convertible Promissory Note [Member] | Christopher Wetzel [Member] | Common Stock [Member]

Aggregate principal amount of debt

$ 70,510

Convertible Promissory Note [Member] | Joseph Eisenberger [Member] | Common Stock [Member]

Aggregate principal amount of debt

$ 423,060

Convertible Promissory Note [Member] | Ross DiMaggio [Member] | Common Stock [Member]

Aggregate principal amount of debt

$ 56,408

Convertible Promissory Note [Member] | David W. Unger [Member] | Common Stock [Member]

Aggregate principal amount of debt

$ 84,612

Convertible Promissory Note [Member] | Brio Capital Maser Fund, Ltd [Member] | Common Stock [Member]

Aggregate principal amount of debt

239,734

Convertible Promissory Note [Member] | Securities Purchase Agreement [Member] | Christopher Wetzel [Member]

Aggregate principal amount of debt

$ 25,000

Debt instrument maturity date

Aug. 18, 2021

Debt conversion, description

(i) $25,000 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the "Note") due August 18, 2021, based on $1.00 for each $0.90909 paid by Wetzel

Term of warrants

5 years

Aggregate number of warrants to purchase shares

5,000

Exercise price of warrants per share

$ 30

Proceeds from issuance of convertible debt

$ 25,000

Original issue discount amount

$ 0

Debt instrument conversion price per share

$ 0.39

Convertible Promissory Note [Member] | Securities Purchase Agreement [Member] | Joseph Eisenberger [Member]

Aggregate principal amount of debt

$ 165,000

Debt instrument maturity date

Sep. 30, 2021

Debt conversion, description

(i) $165,000 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the "Note") due September 30, 2021, based on $1.00 for each $0.90909 paid by Eisenberger

Term of warrants

5 years

Aggregate number of warrants to purchase shares

7,500

Exercise price of warrants per share

$ 30

Proceeds from issuance of convertible debt

$ 150,000

Original issue discount amount

$ 15,000

Debt instrument conversion price per share

$ 0.39

Convertible Promissory Note [Member] | Securities Purchase Agreement [Member] | Ross DiMaggio [Member]

Aggregate principal amount of debt

$ 27,500

Debt instrument maturity date

Aug. 28, 2021

Debt conversion, description

(i) $27,500 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the "Note") due August 28, 2021, based on $1.00 for each $0.90909 paid by DiMaggio

Term of warrants

5 years

Aggregate number of warrants to purchase shares

1,000

Exercise price of warrants per share

$ 30

Proceeds from issuance of convertible debt

$ 20,000

Original issue discount amount

$ 7,500

Debt instrument conversion price per share

$ 0.39

Convertible Promissory Note [Member] | Securities Purchase Agreement [Member] | David W. Unger [Member]

Aggregate principal amount of debt

$ 33,000

Debt instrument maturity date

Aug. 18, 2021

Debt conversion, description

(i) $33,000 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the "Note") due August 18, 2021, based on $1.00 for each $0.90909 paid by Unger

Term of warrants

5 years

Aggregate number of warrants to purchase shares

1,500

Exercise price of warrants per share

$ 30

Proceeds from issuance of convertible debt

$ 30,000

Original issue discount amount

$ 3,000

Debt instrument conversion price per share

$ 0.39

Convertible Promissory Note [Member] | Securities Purchase Agreement [Member] | Osher [Member]

Aggregate principal amount of debt

$ 181,500

Debt instrument maturity date

Sep. 30, 2021

Debt conversion, description

(i) $181,500 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the "Note") due September 30, 2021, based on $1.00 for each $0.90909 paid by Osher

Term of warrants

5 years

Aggregate number of warrants to purchase shares

8,250

Exercise price of warrants per share

$ 30

Proceeds from issuance of convertible debt

$ 165,000

Original issue discount amount

$ 16,500

Debt instrument conversion price per share

$ 0.39

Convertible Promissory Note [Member] | Securities Purchase Agreement [Member] | Brio Capital Maser Fund, Ltd [Member]

Aggregate principal amount of debt

$ 93,500

Debt instrument maturity date

Sep. 30, 2021

Debt conversion, description

(i) $93,500 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the "Note") due September 30, 2021, based on $1.00 for each $0.90909 paid by Brio

Term of warrants

5 years

Aggregate number of warrants to purchase shares

4,250

Exercise price of warrants per share

$ 30

Proceeds from issuance of convertible debt

$ 85,000

Original issue discount amount

$ 8,500

Debt instrument conversion price per share

$ 0.39

Convertible Promissory Note [Member] | Amended Convertible Debt Agreement [Member] | Christopher Wetzel [Member]

Aggregate principal amount of debt

$ 27,500

Debt instrument maturity date

Oct. 20, 2021

Aggregate number of warrants to purchase shares

70,510

Exercise price of warrants per share

$ 0.59

Proceeds from issuance of convertible debt

$ 25,000

Original issue discount amount

$ 2,500

Convertible Promissory Note [Member] | Amended Convertible Debt Agreement [Member] | Joseph Eisenberger [Member]

Debt instrument maturity date

Oct. 20, 2021

Aggregate number of warrants to purchase shares

423,060

Exercise price of warrants per share

$ 0.59

Convertible Promissory Note [Member] | Amended Convertible Debt Agreement [Member] | Ross DiMaggio [Member]

Aggregate principal amount of debt

$ 22,000

Debt instrument maturity date

Oct. 20, 2021

Aggregate number of warrants to purchase shares

56,408

Exercise price of warrants per share

$ 0.59

Proceeds from issuance of convertible debt

$ 20,000

Original issue discount amount

$ 2,000

Convertible Promissory Note [Member] | Amended Convertible Debt Agreement [Member] | David W. Unger [Member]

Debt instrument maturity date

Oct. 20, 2021

Aggregate number of warrants to purchase shares

84,612

Exercise price of warrants per share

$ 0.59

Convertible Promissory Note [Member] | Amended Convertible Debt Agreement Two [Member] | Brio Capital Maser Fund, Ltd [Member]

Debt instrument maturity date

Oct. 20, 2021

Aggregate number of warrants to purchase shares

239,734

Exercise price of warrants per share

$ 0.59

Convertible Promissory Note [Member] | Amended Convertible Debt Agreement Three [Member] | Osher [Member]

Debt instrument maturity date

Oct. 20, 2021

Aggregate number of warrants to purchase shares

465,366

Exercise price of warrants per share

$ 0.59

Convertible Promissory Debent_4

Convertible Promissory Debentures - Schedule of Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Convertible notes payable	$ 616,500
Original issue discount	(19,667)
Debt discount	(78,165)
Total convertible notes payable	518,668
Convertible Promissory Note One [Member]
Convertible notes payable	385,000
Convertible Promissory Note Two [Member]
Convertible notes payable	50,000
Convertible Promissory Note Three [Member]
Convertible notes payable	$ 181,500

Convertible Promissory Debent_5

Convertible Promissory Debentures - Schedule of Convertible Notes Payable (Details) (Parenthetical)	Sep. 17, 2020	Jun. 23, 2020	Jan. 28, 2020
Convertible Promissory Note One [Member]
Debt instrument interest rate			0.00%
Debt instrument maturity date			Oct. 20, 2021
Convertible Promissory Note Two [Member]
Debt instrument interest rate		0.00%
Debt instrument maturity date		Oct. 20, 2021
Convertible Promissory Note Three [Member]
Debt instrument interest rate	0.00%
Debt instrument maturity date	Oct. 20, 2021

Convertible Promissory Debent_6

Convertible Promissory Debentures - Schedule of Principal Payments Due on Convertible Promissory Debentures (Details)	Dec. 31, 2020USD ($)
Debt Disclosure [Abstract]
2021	$ 518,668

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Oct. 19, 2020	Dec. 31, 2019	Dec. 31, 2020
Stock issued during period value
Common stock shares authorized		1,000,000,000	1,000,000,000
Common stock par value		$ 0.0001	$ 0.0001
Common stock shares outstanding		500,000	35,201,513
Stock issued during period shares on acquisition	33,685,876
Third Parties [Member]
Stock issued during period shares			1,015,344
Restricted Stock [Member]
Stock issued during period shares			500,000
Stock issued during period value			$ 50

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - Employment Agreements [Member] - USD ($)	2 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020
Mr. Joyce [Member]
Annual base salary		$ 455,000
Maximum bonus compensation percentage		50.00%
Beneficial ownership target percentage		9.00%
Compensation expense	$ 0	$ 418,842
Employee benefits	0	22,516
COO [Member]
Compensation expense	0	233,981
Employee benefits	$ 0	$ 22,024

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	Dec. 31, 2020USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carry forwards for federal and state	$ (1,229,000)
Net operating loss carryforwards limitation percentage	80.00%

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rates and Effective Tax Rate (Details)	2 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Statutory U.S. federal rate	21.00%	21.00%
State income tax, net of federal benefit	7.00%	7.00%
Permanent differences	0.00%	0.00%
Valuation allowance	(28.00%)	(28.00%)
Provision for income taxes	0.00%	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 352,912	$ 434
Valuation allowances	(352,912)	(434)
Total

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)	2 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020
Earnings Per Share [Abstract]
Net loss attributable to the common stockholders	$ (1,550)	$ (1,259,590)
Basic weighted average outstanding shares of common stock	500,000	7,351,272
Dilutive effect of options and warrants
Diluted weighted average common stock and common stock equivalents	500,000	7,351,272
Loss per share: Basic and diluted	$ 0	$ (0.17)

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Feb. 10, 2021	Jan. 14, 2021	Dec. 31, 2019	Dec. 31, 2020
Original issue discount amount				$ 78,165
Stock issued during period value
Subsequent Event [Member]
Stock issued during period shares		47,000
Stock issued during period value		$ 82,250
Convertible Promissory Note [Member] | Osher [Member] | Subsequent Event [Member]
Aggregate principal amount of debt	$ 110,000
Debt instrument maturity date	Feb. 11, 2022
Debt conversion description	(i) $110,000 aggregate principal amount of Note due February 11, 2022 based on $1.00 for each $0.90909 paid by Osher
Term of warrants	5 years
Exercise price of warrants per share	$ 1.20
Proceeds from issuance of convertible debt	$ 100,000
Original issue discount amount	$ 10,000
Debt instrument conversion price per share	$ 0.70
Convertible Promissory Note [Member] | Osher [Member] | Subsequent Event [Member] | Brio [Member]
Aggregate principal amount of debt	$ 110,000
Debt instrument maturity date	Feb. 11, 2022
Debt conversion description	(i) $110,000 aggregate principal amount of Note due February 11, 2022 based on $1.00 for each $0.90909 paid by Osher
Term of warrants	5 years
Exercise price of warrants per share	$ 1.20
Proceeds from issuance of convertible debt	$ 100,000
Original issue discount amount	$ 10,000
Debt instrument conversion price per share	$ 0.70
Convertible Promissory Note [Member] | Osher [Member] | Subsequent Event [Member] | Maximum [Member]
Aggregate number of warrants to purchase shares of common stock	157,143
Convertible Promissory Note [Member] | Osher [Member] | Subsequent Event [Member] | Maximum [Member] | Brio [Member]
Aggregate number of warrants to purchase shares of common stock	157,143